abiraterone plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
randomized controlled trial
androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily)
androgen-deprivation therapy plus dual placebos
metastatic, hormone-sensitive prostate cancer
STAMPEDE abiraterone, 2017 NCT00268476
abiraterone plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
randomized controlled trial
abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily)
ADT alone
metastatic, hormone-sensitive prostate cancer
52% of the patients had metastatic disease, 20% had node-positive or node-indeterminate nonmetastatic disease, and 28% had node-negative, nonmetastatic disease; 95% had newly diagnosed disease